Panzyga IVIG
Phase 2Small molecule
Panzyga IVIG is one of 48 small molecule programs targeting Neuropathy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
114 competitors in Neuropathy
#DrugCompanyPhaseTrials
1Vimpat
UCBPhase 3
Avandia
Alnylam PharmaceuticalsPhase 3
Asceniv
CSL BehringPhase 3
Savella
AbbViePhase 3
Avicel
SSanthera Pharmaceuticals
Phase 3
Prilosec
DDexcel Pharma Technologies Ltd.
Phase 3
Claritin
PPerrigo Company
Phase 3
Glutamine
SanofiPhase 3
Curcumin
Merck & Co.Phase 3
Taxol
TevaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Panzyga IVIG. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- EEndeavor Health